Novo Nordisk says degludec insulin outperforms Sanofi rival
Fri,24 Jun 2011 05:00 PM PDT
Reuters - COPENHAGEN (Reuters) - Studies showed Novo Nordisk's insulin degludec lowered blood sugar levels with significantly reduced rates of hypoglycaemia when compared with rival Sanofi's Lantus, the Danish firm said on Saturday. Full Story1

Fri,24 Jun 2011 05:00 PM PDT
Reuters - COPENHAGEN (Reuters) - Studies showed Novo Nordisk's insulin degludec lowered blood sugar levels with significantly reduced rates of hypoglycaemia when compared with rival Sanofi's Lantus, the Danish firm said on Saturday. Full Story1
Amylin study shows insignificant heart rhythm link Fri,24 Jun 2011 04:29 PM PDT Reuters - SAN DIEGO (Reuters) - Analysis of an earlier trial found a "clinically insignificant" link between changes in heart rhythms and use of Bydureon, a long-acting diabetes drug being developed by Amylin Pharmaceuticals, Eli Lilly and Alkermes. Full Story1 |
FDA rejects Pain, Pfizer anti-abuse painkiller Fri,24 Jun 2011 03:46 PM PDT Reuters - BANGALORE (Reuters) - Pfizer Inc and Pain Therapeutics Inc said U.S. health regulators declined to approve their abuse-resistant painkiller Remoxy, less than a week after a similar Pfizer drug was cleared for sale, sending Pain's stock crashing Friday. Full Story1 |
Abbott says blood sugar monitoring devices stolen Fri,24 Jun 2011 02:45 PM PDT Reuters - (Reuters) - Abbott Laboratories said it was working with authorities to retrieve one tractor-trailer shipment of blood glucose monitoring products that was reported stolen on June 19. Full Story1 |
Endo recalls two lots of pain drug Fri,24 Jun 2011 02:40 PM PDT Reuters - (Reuters) - Endo Pharmaceuticals Holdings Inc said it recalled two lots of its pain drug Endocet as it may contain incorrect tablets that have a higher dose of widely used analgesic, acetaminophen. Full Story1 |
Sanofi diabetes drug shown to work as well as Byetta Fri,24 Jun 2011 02:30 PM PDT Reuters - SAN DIEGO (Reuters) - A trial of Sanofi's experimental once-daily drug for Type 2 diabetes, Lyxumia, found that it worked as well as Byetta, a similar drug sold by Amylin and Eli Lilly and Co that is injected twice a day. Full Story1 |
Analysis: Scientists getting closer to artificial pancreas Fri,24 Jun 2011 02:05 PM PDT Reuters - Full Story1 |
Heart risks lower in men who get enough vitamin D Fri,24 Jun 2011 12:19 PM PDT Reuters - NEW YORK (Reuters Health) - Men who consume the recommended amount of vitamin D are somewhat less likely to suffer a heart attack or stroke than those who get little of the vitamin in their diets, a large U.S. study suggests. Full Story1 |
FDA urges caution on Amgen, J&J anemia drugs Fri,24 Jun 2011 10:37 AM PDT Reuters - NEW YORK (Reuters) - Health regulators urged on Friday more conservative dosing for widely used anemia drugs from Amgen Inc and Johnson & Johnson because of the risk of heart problems. Full Story1 |
Dutch may label some cannabis as a hard drug Fri,24 Jun 2011 10:27 AM PDT Reuters - AMSTERDAM (Reuters) - The Netherlands, famous for its liberal soft drugs policies, said on Friday it may label some highly concentrated forms of cannabis as a hard drug on a par with cocaine or heroin, because of the risk of addiction. Full Story1 |
Prenatal folic acid doesn't boost sons' fertility Fri,24 Jun 2011 10:26 AM PDT Reuters - NEW YORK (Reuters Health) - Young men whose mothers took folic acid supplements while pregnant did not grow up to produce healthier sperm, a small Danish study has found. Full Story1 |
Kidney improvement sustained by Abbott drug: study Fri,24 Jun 2011 10:24 AM PDT Reuters - NEW YORK (Reuters) - Diabetics with moderate to severe chronic kidney diseaseshowed significant and sustained improvement in kidney function through 52 weeks of treatment with a novel drug being developed by Abbott Laboratories, according to data from a midstage clinical trial. Full Story1 |
Some small risks to antidepressants in pregnancy Fri,24 Jun 2011 08:22 AM PDT Reuters - NEW YORK (Reuters Health) - Two antidepressants appear to be associated with a small risk of birth defects, according to a new analysis based on national data from Finland. Full Story1 |
Newport ads target black youth: Stanford study Fri,24 Jun 2011 07:54 AM PDT Reuters - SAN FRANCISCO (Reuters) - Cigarette maker Lorillard Inc targeted California school neighborhoods with high proportions of African-American students for its Newport menthol cigarettes, Stanford University said on Friday. Full Story1 |
Experts warn U.S. to boost Alzheimer's funding Fri,24 Jun 2011 07:36 AM PDT Reuters - CHICAGO (Reuters) - Alzheimer's experts urged U.S. lawmakers on Thursday to increase funding for research of the debilitating disease and to push international policymakers to pay more attention to its global impact. Full Story1 |
|
email: info@als-alexander.org or interalex2@gmail.com
No comments:
Post a Comment